December **03-04**, 2026 | **Munich**, Germany | **#EmRNA**

REGISTER NOW

Eurostars Grand Central Hotel | Arnulfstraße 35 | 80636 München, Germany

CONFERENCE & NETWORKING & EXHIBITION

3rd mRNA & CGT: CMC, Process Development and Manufacturing

This next-edition summit brings together leading experts from biotech, pharma, CDMOs, and academia to address the latest **technical, regulatory, and operational challenges** shaping the development and GMP manufacturing of **mRNA vaccines, RNA therapeutics, and cell & gene therapies**.


As the field advances toward **higher potency constructs, automated production lines, intensified processes, and evolving regulatory frameworks**, this year's agenda places a strong focus on **CMC strategy, end-to-end process development, analytical modernization**, and accelerating tech transfer for clinical and commercial success.

Participants will gain **practical, implementation-driven insights** through real-world case studies on establishing scalable mRNA and CGT platforms, ensuring regulatory readiness, integrating digital technologies, and improving robustness across the entire product lifecycle—from early development to commercial supply.


Whether you are advancing early process characterization or overseeing commercial manufacturing, this summit provides **critical technical knowledge, peer learning, and cross-functional collaboration** to support the next generation of advanced therapies.



Dr. Roland Pach, CH
Global Expert, Cell and Gene Therapy Analytics
Roche




Dr. Steven Wolk, US
Founder & Chief Consultant
Sinawali Biotechnology Solutions



Dr Uche Odunze, NL
Principal Scientist
Lonza



Dr. Philip Grossen, DE
Principal Scientist
Roche



Dr. Ioannis Rabias, GR
Head of Quality Control Department/ Qualified Person I Member of the Group of Experts for Human Vaccines
Hellenic Pasteur Institute I EDQM



Dr. Rajesh Krishnan, CA
Vice President- Delivery Technology and Development
Providence Therapeutics



Dr. Ashiqul Haque, BE
Chief Scientific Officer
Quantoom Biosciences




Dr. Melanie Kerst, DE
CEO Eurofins Genomics Europe Pharma and Diagnostics Products & Services Synthesis GmbH
Eurofins Genomics




Alexandre Fouassier, UK
Business Development Director
eXmoor Pharma



Dr. Amey Bandekar, US
Associate Director Drug Product Development
Sanofi



Dr. Miloud G. Nichane, FR
Process Validation Head
LFB



Dr. Pablo Mancheño Corvo, ES
Technical Director of Advanced Therapies Units
Hospital Universitario Fundación Jimenez Diaz



Laurens Vergauwen, BE
EMEA Senior Process Development Scientist
Merck Group



Dr. Ketaki Deshmukh, US
Senior Scientist
Novo Nordisk



Natascha Missbach, AT
CEO & Co-Founder
nagene GmbH



Dr. Bojan Kopilovic, UK
Postdoctoral Research Associate
The University of Sheffield



Harvey Branton, UK
Senior Translation Consultant, Project Lead
eXmoor Pharma Concepts Ltd

SPONSORSHIP SPEAKING & EXHIBITION OPPORTUNITIES AVAILABLE

Partners & Sponsors:

nagene | Quantoom Biosciences | eurofins Genomics | RD-Biotech Janvier Group | Hongene Biotech | Promega

etapapharma

December **03-04**, 2026 | **Munich**, Germany | **#EmRNA**

REGISTER NOW

CONFERENCE & NETWORKING & EXHIBITION

3rd mRNA & CGT: CMC, Process Development and Manufacturing

Sponsorship-related questions to: **gabriela.vladimirova@vonlanthen-conferences.com** / **gabriela@etapahub.com**

Key Practical Learning Points

CMC, Process Development & Manufacturing Strategy

- Build future-proof CMC strategies tailored to mRNA and CGT modalities, incorporating regulatory expectations, platform lifecycle management, and accelerated development pathways
- Implement intensified upstream and downstream processes to increase yield, purity, and scalability for mRNA, LNPs, and viral vectors

Manufacturing Platforms, Automation & Tech Transfer

- Deploy closed, modular, and digitalized manufacturing platforms to improve flexibility, contamination control, and global tech transfer readiness
- Optimize raw material strategies—including nucleotides, enzymes, lipids, and plasmids—to mitigate supply chain risk, variability, and qualification challenges

Quality, Analytics & Regulatory Expectations

- Advance and validate analytical methods for potency, identity, purity, and stability of mRNA, LNP formulations, and gene-modified products
- Address global regulatory updates for CMC dossier requirements, comparability expectations, platform-based submissions, and evolving RNA-specific guidance

Formulation, LNP Technologies & Next-Gen Constructs

- Design and scale LNP formulations with improved reproducibility, encapsulation efficiency, release profiles, and in vivo performance
- Explore next-generation mRNA constructs, self-amplifying systems, circular RNA, and emerging delivery technologies to enhance expression, stability, and therapeutic effect

Digitalization, PAT & Real-Time Process Control

- Integrate digital tools, automation, AI-driven analytics, and PAT (Process Analytical Technology) to enable real-time monitoring, control, and decision-making during GMP manufacturing
- Ensure process comparability across batches, sites, and scale changes using risk-based strategies, robust control frameworks, and strong data governance
- Ensure comparability across batches and process changes, including best practices for bridging data and risk-based approaches
- Explore next-generation mRNA constructs and delivery technologies poised to improve expression, stability, and therapeutic impact







Who should attend

Chief Executives, Vice Presidents, Directors, Heads, Leaders, and Managers specialising in:

- CMC (Chemistry, Manufacturing, and Controls)
- Process Development & Scale-Up
- Analytical Science & Product Characterisation
- mRNA and RNA Therapeutics
- Plasmid DNA (pDNA), In-Vitro Transcription & RNA Technologies
- Formulation & Lipid Nanoparticles (LNP)
- Drug Substance and Drug Product Development
- Bioprocessing, Purification & Production Engineering
- Manufacturing Science & Technology (MSAT)
- Quality Assurance (QA), Quality Control (QC) & Quality by Design (QbD)
- Good Manufacturing Practices (GMP)
- Process Analytical Technology (PAT)
- Regulatory Affairs & Compliance
- Research & Development (R&D)
- Clinical Development & Safety
- Commercialisation & Supply Chain Management
- Oncology, Vaccines & Cancer Immunotherapy
- Innovation Chemistry & Impurities
- Comparability & Lifecycle Management

December **03-04**, 2026 | **Munich**, Germany | **#EmRNA**

REGISTER NOW

CONFERENCE & NETWORKING & EXHIBITION

3rd mRNA & CGT: CMC, Process Development and Manufacturing

Sponsorship-related questions to: **gabriela.vladimirova@vonlanthen-conferences.com** / **gabriela@etapahub.com**

Partners & Sponsors

nagene GmbH

nagene is a Vienna-based biotechnology company offering fast and reliable synthetic DNA products, including DNA fragments and plasmids of high and complex gene constructs, manufactured using GMP-compliant processes. In parallel, nagene is developing next-generation cell-free DNA manufacturing technologies aimed at highly regulated applications such as mRNA, gene and cell therapies, with a strong focus on quality, scalability, and CMC requirements.

Quantoom Biosciences

Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization. Quantoom Biosciences is a trade name of Phoenix Biosciences SA.

Eurofins Genomics

Eurofins Genomics represents the genomic division within the Eurofins Scientific Group. With facilities in Europe, the United States and Asia, Eurofins Genomics is an internationally leading provider of DNA sequencing and genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The European branch is headquartered in Ebersberg, Germany.

RD-Biotech

RD-Biotech is a French biotechnology company providing high-quality **plasmid DNA as a critical starting material for mRNA and advanced therapy manufacturing**. With over 24 years of expertise, the company supports CMC and process development programs from **plasmid design** and **optimization** through **cloning, production and comprehensive QC**. Its flexible platform delivers **R&D**, **High Quality** and **GMP manufacturing**, for mRNA, saRNA, AAV, lentiviral and CAR-T applications. RD-Biotech helps biopharma and CDMO partners secure reliable, scalable DNA templates tailored to their process and manufacturing requirements.

Hongene Biotech

Since 1998, Hongene Biotech has been a trusted name in nucleic acid manufacturing. Backed by nearly 30 years of RNA-focused expertise, we partner with biotech and pharma innovators to accelerate development with precision and purpose. Our vertically-integrated model — spanning raw materials to advanced CDMO services — reduces handoffs, shortens timelines and lowers risk across the value chain.

December **03-04**, 2026 | **Munich**, Germany | **#EmRNA**

REGISTER NOW

CONFERENCE & NETWORKING & EXHIBITION

3rd mRNA & CGT:
CMC, Process Development and Manufacturing

Sponsorship-related questions to: **gabriela.vladimirova@vonlanthen-conferences.com / gabriela@etapahub.com**

Upcoming Pharma Events

Aseptic Processing, Visual Inspection & Packaging Summit
February 25-26, 2027 | Amsterdam & Online | #EAsepticProcessing

11th Impurities: Genotoxic, Nitrosamine & Beyond Summit
April 7-9, 2027 | Vienna & Online | #Egenotoxic

Future Food & Nutrition Summit 2027
September 14-15, 2027 | Berlin, Germany | #EFutureNutrition


10th HPAPI: Development and Manufacturing of HPAPI (APIs)
September 22-23, 2027 | Europe | #Ehpapi



For more info contact:
gabriela.vladimirova@vonlanthen-conferences.com / gabriela@etapahub.com
or visit our new website:
www.etapapharma.com

Join Our LinkedIn Communitiy

Scan the QR code or search for our LinkedIn community:
mRNA Connect



etapapharma

DAY 1 | Strategy, Compliance & Analytical Foundations

SETTING THE STAGE: QUALITY, STRATEGY & CMC INTEGRATION IN MRNA & CGT

08:00 **Registration and Welcome Coffee**

08:25 **Opening by Moderator**

08:30



Unveiling dsRNA impurities in mRNA therapeutics: An ongoing comprehensive industry review of origins, analytics, control strategies, and regulatory challenges for safe vaccine and therapy development

Dr. Roland Pach, CH | Global Expert, Cell and Gene Therapy Analytics | Roche

09:00 SPEED NETWORKING

09:25



Next generation RNA manufacturing: Platforms, processes and product considerations

Dr Uche Odunze, NL | Principal Scientist | Lonza

09:55 NETWORKING / COFFEE BREAK


10:20



Manufacturing of personalized cancer vaccines at speed - A Providence experience

Dr. Rajesh Krishnan, CA | Vice President- Delivery Technology and Development | Providence Therapeutics

10:50



De-Risking ATMP tech transfer from Lab to GMP

Dr. Pablo Mancheño Corvo, ES | Technical Director of Advanced Therapies Units | Technical Director of Advanced Therapies Units

11:20 SPONSORED SPEAKING SLOT



From DNA template to patient: Driving speed, quality and CMC readiness in mRNA Manufacturing

- Role of DNA template quality in driving IVT efficiency, product quality, and downstream mRNA performance
- Supporting personalized medicine through fast, customizable DNA solutions aligned with customer-specific and regulatory requirements
- Ensuring reproducibility and regulatory readiness through GMP-like DNA production, advanced testing, and fully traceable processes

Dr. Melanie Kerst, DE | CEO Eurofins Genomics Europe Pharma and Diagnostics Products & Services Synthesis GmbH | Eurofins Genomics

11:40 OPEN SPONSORSHIP OPPORTUNITIES (10-20-30-40 MIN)

Sponsorship-related questions to:
gabriela.vladimirova@vonlanthen-conferences.com / gabriela@etapahub.com

12:00 BUSINESS LUNCH

13:00 EXHIBITION / NETWORKING / COFFEE BREAK

REGULATORY & STRATEGIC ALIGNMENT

13:20




Tech transfer & CDMO collaboration: practical case

- Criticality of sponsor / CDMO interaction
- Beyond technology transfer: product & process knowledge

Dr. Miloud G. Nichane, FR | Process Validation Head | LFB

13:50



QC testing according to European Pharmacopoeia mRNA standards

Dr. Ioannis Rabias, GR | Head of Quality Control Department/ Qualified Person | Member of the Group of Experts for Human Vaccines | Hellenic Pasteur Institute I EDQM

14:20

CMC for gene therapy and cancer immunotherapies

14:50

OPEN SPONSORSHIP OPPORTUNITIES (10-20-30-40 MIN)

Sponsorship-related questions to:
gabriela.vladimirova@vonlanthen-conferences.com / gabriela@etapahub.com

15:10 EXHIBITION / NETWORKING / COFFEE BREAK

ANALYTICAL, CONTROL STRATEGY & DIGITALIZATION

15:40



Strategy for potency determination of gene therapy products

Dr. Roland Pach, CH | Global Expert, Cell and Gene Therapy Analytics | Roche

16:00



Raman spectroscopy as a universal PAT tool: Real-Time process monitoring across AAV, lentiviral vector, and mRNA platforms


- Real-time CQA tracking in TFF for viral vector
- Monitoring mRNA synthesis and NTP depletion during IVT
- Key Lessons Learned Implementing Raman Across Modalities

Laurens Vergauwen, BE | EMEA Senior Process Development Scientist | Merck Group

BROADER ADOPTION & MANUFACTURING INNOVATION

16:25

SPONSORED SPEAKING SLOT



Dr. Ashiqul Haque, BE | Chief Scientific Officer | Quantoom Biosciences

Quantoom Biosciences

16:45



Advancing Cell-Free DNA manufacturing: Early results from a Cell-Free platform

- Practical insights into GMP-compliant DNA manufacturing, including the production of complex and challenging gene constructs for regulated applications
- Early results from the development of a next-generation cell-free DNA manufacturing approach, building on established synthetic DNA production workflows
- Key process, quality, and scalability considerations when transitioning towards cell-free DNA manufacturing for mRNA and gene therapy development

Natascha Missbach, AT | CEO & Co-Founder | nagene GmbH

17:05 EXHIBITION / NETWORKING

17:20	**Innovation readiness and manufacturing enablement**
17:45	**Formulation development, Digital and Modeling**
18:10	**Q&A/PANEL DISCUSSION** (All Speakers of the Day Are Invited) **& MODERATOR'S CLOSING REMARKS**

What is still slowing down mRNA & CGT CMC?

- Are current CMC frameworks fit for advanced modalities?
- What are regulators still most concerned about?
- Platform approaches vs product-specific development
- Biggest bottlenecks in analytical characterization
- How much standardization is realistically possible?
- Can automation reduce CMC risk?
- What still prevents broader adoption?

18:40	**EXHIBITION / NETWORKING**
19:00	**BUSINESS DINNER & NETWORKING**

Follow #EtapaPharma On Social Media

#EtapaPharma

@etapa_pharma

#EmRNA

DAY 2 | Process Development, Scale-Up & Manufacturing Optimization

08:15 **Registration and Welcome Coffee**

08:40 **Opening by Moderator**

CMC STRATEGY SIMULATION WORKSHOP

08:45




Workshop

Design the CMC Roadmap for an mRNA Therapy

Harvey Branton, UK | Senior Translation Consultant, Project Lead | eXmoor Pharma Concepts Ltd

Alexandre Fouassier, UK | Business Development Director | eXmoor Pharma

09:45 EXHIBITION / NETWORKING

FROM PLATFORM TO PRODUCT: PROCESS, FORMULATION & DELIVERY TECHNOLOGIES

10:05



Optimising ATMP formulations

Dr. Philip Grossen, DE | Principal Scientist | Roche

10:30



Formulation and stabilization of mRNA-LNP vaccines

Dr. Ketaki Deshmukh, US | Senior Scientist | Novo Nordisk

10:55



"RNAbox™: A Scalable platform for the GMP-ready continuous manufacturing and encapsulation of RNA medicines

- Design and scale modular, closed systems for robust, reproducible RNA–LNP encapsulation
- Control critical process parameters to enhance encapsulation efficiency, comparability, and product quality
- Integrate CMC and PAT strategies to enable tech transfer, regulatory readiness, and flexible manufacturing

Dr. Bojan Kopilovic, UK | Postdoctoral Research Associate | The University of Sheffield

11:20 **Next-generation LNP technologies**

11:45 **Reprogramming NK cells with mRNA-LNPs: A non-viral strategy to boost antitumor function**

12:10 EXHIBITION / NETWORKING / COFFEE BREAK

12:40



Formulation & process development considerations for nonviral gene delivery

- Rationale for LNP design
- Intracellular trafficking for LNP optimization
- Manufacturing and scale up of LNP DP

Dr. Amey Bandekar, US | Associate Director Drug Product Development | Sanofi

GENE EDITING & ADVANCED THERAPEUTIC PLATFORMS

13:10



State of the art and PD considerations for the current holy grails of CRISPR gene editing: Targeted delivery and large knockins

- We are very good at making small edits in the genome with CRISPR enzymes. Our ability to make large changes or insert an entire gene, which will create the ability to treat many disease variants with a single therapeutic, still presents a significant challenge
- Recent advances in both these areas will be discussed, as well as the challenges and opportunities in process development for the various possible solutions to these technical hurdles

Dr. Steven Wolk, US | Founder & Chief Consultant | Sinawali Biotechnology Solutions

13:35 **Q&A/PANEL DISCUSSION** (All Speakers of the Day Are Invited) I **MODERATOR'S CLOSING REMARKS & THE END OF THE SUMMIT**

How do we industrialize the future of mRNA & CGT?

- Can mRNA manufacturing become truly modular?
- What is still limiting LNP performance?
- Continuous manufacturing — reality or hype?
- How scalable are personalized therapies?
- What will future DP manufacturing look like?
- Can non-viral delivery replace viral systems?
- Where will AI/automation have the biggest impact?

14:00 **BUSINESS LUNCH & NETWORKING**




Dr. Roland Pach, CH | Global Expert, Cell and Gene Therapy Analytics | Roche

Dr. Roland Pach holds a PhD in molecular parasitology from the University Fribourg analyzing the intracellular trafficking of transgenic RNA in human pathogens. Prior to Roche, he led the analytical development department at Berna Biotech (former Swiss Vaccine and Serum Institute) and the QC department of bio-process development at Merck Serono. Roland has been the global CMC analytical technical lead in the cancer vaccines and cell and gene therapy (CGT) area of Roche for more than 10 years. In his assigned area, he represents Roche in external development projects, industrial consortiums like CGT BioPhorum and numerous due diligences of in-licensing candidates or companies in the CGT fields. In his previous role at Roche as global technical development leader, he led successful new formats like immunotoxins from pre-clinics into entry to human (EiH).



Dr. Amey Bandekar, US | Associate Director Drug Product Development | Sanofi

Amey Bandekar is an Associate Director in Biologics Drug Product Development& Manufacturing Organization at Sanofi. He primarily leads and provides oversight to the Drug Product development activities for viral and non-viral gene therapy programs. He obtained his Ph.D from New York University in Chemical Engineering with focus on developing lipid-based drug delivery nanocarriers for cancer therapy. Prior to joining Sanofi, Amey worked at Shire (Takeda) on early and late-stage protein therapeutic programs along with their mRNA/LNP platform.



Dr. Steven Wolk, US | Founder & Chief Consultant | Sinawali Biotechnology Solutions

Steve is the Founder and Chief Consultant for Sinawali Biotechnology Solutions. He was formerly the Vice President of Chemistry & Boulder Site Head for Editas Medicine, where he led the Advanced Technology, Analytical Sciences & Structural Biology, and Process Chemistry teams. He received his bachelor's degree in Chemistry from UC San Diego, where he received the Harold Urey Award. He completed his Ph.D. work in Biophysical Chemistry at UC Berkeley under Dr. Ignacio Tinoco, where he used 2D-NMR and other spectroscopic techniques to characterize nonstandard DNA structures. In addition to an extensive history directing analytical groups for characterizing oligonucleotides, proteins, small molecules & polymers, he has led efforts to develop new technologies for delivery of CRISPR therapeutics, and has broad experience in leadership, including management, developing future leaders, creating/revising governance programs, and as a site head.



Dr. Miloud G. Nichane, FR | Process Validation Head | LFB

Miloud G. NICHANE currently serves as GMP Auditor and Head of Process Validation at LFB. He holds a PhD in Molecular and Cellular Biology, with a doctoral thesis focused on brain development and architect genes. Over the years, Miloud has built a dynamic career across the pharmaceutical landscape, contributing to both global leaders such as GlaxoSmithKline and the Bill & Melinda Gates Foundation, as well as innovative biotech pioneers like Legend Biotech. Driven by a strong commitment to advancing the Belgian and broader European life sciences ecosystem, Miloud has worked on a diverse range of therapeutic modalities—including plasmids, mRNA, monoclonal antibodies, blood-derived proteins, and CAR-T T lymphocytes. His multidisciplinary experience offers a unique perspective on the vast potential of modern biomedicine.



Laurens Vergauwen, BE | EMEA Senior Process Development Scientist | Merck Group

Process Development Scientist in EMEA, Laurens supports customers in the development and optimization of various downstream purification technologies (chromatography, TFF, clarification, sterile and viral filtration). He has gained knowledge about purification strategies for different kinds of biopharmaceuticals, including viral vectors. He obtained his master's degree in Industrial Biochemical Engineering at the University of Leuven (Belgium).



Dr. Ashiqul Haque, BE | Chief Scientific Officer | Quantoom Biosciences

Ashiqul Haque is an accomplished biochemist with over a decade of experience in mRNA-based drug development. He earned his PhD from the University of Tübingen in collaboration with CureVac and TriLink, focusing on mRNA-based gene supplementation and correction therapy for Cystic Fibrosis. His research has led to multiple first-author publications in high-impact journals, including Molecular Therapy and Nature Communications, and he is the inventor on several patents covering chemical modifications of mRNA and lipid/LNP library creation for RNA-based therapeutics. Currently serving as CSO at Quantoom, Ashiqul plays a central role in guiding the company's mRNA and saRNA programs for both vaccination and therapeutic applications. He oversees the full technical and scientific pipeline—from molecular design (antigen, mRNA, and plasmid engineering) to drug substance development (self-amplifying RNA formulated in lipid nanoparticles)—ensuring every stage meets rigorous innovation and quality standards. Ashiqul's blend of deep scientific expertise, patent-backed innovation, and strategic project leadership continues to drive forward the next generation of RNA-based medicines.



Harvey Branton, UK | Senior Translation Consultant, Project Lead | eXmoor Pharma Concepts Ltd

Harvey has 30 years' experience working in bioprocessing. Harvey's knowledge extends through R&D, automation, manufacturing support and production management and working at the interface between R&D and manufacturing. He has led a range of RNA/LNP development projects including the transfer & scale up of Imperial College's self-amplifying mRNA COVID vaccine. Supported the establishment of CPI's RNA Centre of Excellence including a GMP manufacturing facility for RNA / LNP and a training academy to support the upskilling of RNA manufacturing skills and understanding.




Alexandre Fouassier, UK | Business Development Director | eXmoor Pharma

Alexandre's background spans biochemistry, recombinant protein production and cell and gene therapy, including roles at Bio-Techne, Ncardia and CELLforCURE, a CDMO specialising in clinical and commercial-scale ATMP manufacturing. He holds an MSc in Biochemistry from Paris Saclay University and trained as an agronomy engineer at AgroParisTech.



Dr. Rajesh Krishnan, CA | Vice President- Delivery Technology and Development | Providence Therapeutics

Rajesh Krishnan is the VP-Delivery Technology and Development at Providence Therapeutics Holdings Inc. Rajesh is a chemist by training and holds a PhD in Chemistry. He has been working with Providence Therapeutics since 2019. At Providence he oversees all CMC activities from R&D to Tech Transfer and Manufacturing.



Dr. Ioannis Rabias, GR | Head of Quality Control Department/ Qualified Person | Member of the Group of Experts for Human Vaccines | Hellenic Pasteur Institute I EDQM

Dr. Ioannis Rabias is a Chemist and Head of Quality Control, Qualified Person and Quality Control Manager in the Production Unit of Pharmaceutical Products for Human and Veterinary Use of the Hellenic Pasteur Institute. Member of the Scientific Council of the Hellenic Pasteur Institute. Member of the Expert Group on Human Vaccines (15) (Human Vaccines and Sera) of the European Pharmacopoeia of the European Directorate for the Quality of Medicines and Healthcare (EDQM) of the Council of Europe.Member of the Scientific Working Group Therapeutics of the Pasteur Network and Member of the Pasteur Network Vaccine Manufacturing Initiative of the Pasteur Network. Member of the European EUREKA Network from 2021 to present, of the evaluation and funding committee of Eurostars, Innowide, Eureka Fast Track, EIC Accelerator programs.
Lecturer in the Inter Institutional Postgraduate Program VACCINES AND INFECTIOUS DISEASES of the Department of Medicine, School of Health Sciences of the Aristotle University of Thessaloniki and the Department of Biomedical Sciences of the International Hellenic University, Greece.
Lecturer in the Inter Institutional Postgraduate Program entitled 'Cell and Gene Therapies: from bench to bedside and Good Manufacturing Practices' of the Department of Medicine, School of Health Sciences of the University of Patras and the Biomedical Sciences of the University of West Attica, Greece. He has developed microbiological air mapping protocols in collaboration with Professor of University of West Attica George Nikolaidis. The result was the creation of UVITRONICS, the first University of West Attica spin-off company registered in ELEVATE GREECE.
Dr. Ioannis Rabias has been collaborating with the Children's Oncology Unit in Athens Greece and specifically with the ELPIDA Center for Cellular and Gene Therapy, for the development of biopharmaceuticals. As head of the Quality Control Department of the EIP, he provides quality control of product specifications for the start of the phase II clinical study of the Pontificia Universidad Católica de Chile for the development of a vaccine against human respiratory syncytial virus (RSV), which is be conducted in Greece. As head of a Laboratory in a Collaborative Study for the standardization of an in vitro assay for the testing of the potency of human rabies vaccines by ELISA (BSP148) Phase 2 and 3 and in a Collaborative Study for the Creation of a Replacement Lot for the European Pharmacopoeia Diphtheria Toxin Reference Biological Preparation (BSP117) of the European Directorate for the Quality of Medicines and Healthcare (EDQM) of the Council of Europe.



Dr. Melanie Kerst, DE | CEO Eurofins Genomics Europe Pharma and Diagnostics Products & Services Synthesis GmbH | Eurofins Genomics

Melanie Kerst is an experienced executive with over 25 years of leadership experience in the pharmaceutical and life sciences industry. As Business Unit Cluster Manager at Eurofins Genomics, she oversees BioPharma Genomics, Sequencing, and DNA Synthesis, driving strategic development, operational excellence, and business growth. Throughout her career, Melanie has held senior leadership positions in pharmaceutical analytics, quality management, and business development. Her expertise covers analytical development, quality control, regulatory compliance, and CMC requirements, with extensive experience managing multidisciplinary teams and complex pharmaceutical projects. Combining scientific expertise with strategic business leadership, Melanie brings valuable insights into innovation, quality standards, and the evolving needs of the pharmaceutical and biotechnology industries.



Dr Uche Odunze, NL | Principal Scientist | Lonza

Dr Uche Odunze is a Principal Scientist at Lonza where he leads upstream process development and scale-up of mRNA manufacturing. He has more than a decade of experience in RNA design, IVT process development, LNP and polymeric nanoparticle drug delivery. Uche previously worked at Astrazeneca and Nuntius Therapeutics. He holds a PhD in Nanomedicines from UCL.

3rd mRNA & CGT: CMC, Process Development and Manufacturing

Registration Form

December **03-04**, 2026 | **Munich**, Germany

To receive a 10% discount for group bookings, please contact our sales person.

CHOOSE YOUR PACKAGE

Attendee packages* *price per person	Standard Price
☐ **Pharma/Biotech** *10% off for Group Booking (2+)* — *2-Day Conference Pass, Panel Discussions, Networking sessions,Coffee breaks and lunches, Business dinner, Documentation package.*	€1199
☐ **Solution Provider** *10% off for Group Booking (2+)* — *2-Day Conference Pass, Panel Discussions, Networking sessions,Coffee breaks and lunches, Business dinner, Documentation package.*	€2499
☐ **Documentation** — *Access to authorized speaker's presentations*	€699

→ *Hotel accommodation & travel costs are not included in the registration fee*

To register for the Summit, please provide the details below. ** Required fields*

1

Name*: Surname*:

Position*:

E-mail*:

Special dietary requirements: ☐ *Vegetarian* ☐ *Gluten-free* ☐ *Other (please specify)* _____

2

Name*: Surname*:

Position*:

E-mail*:

Special dietary requirements: ☐ *Vegetarian* ☐ *Gluten-free* ☐ *Other (please specify)* _____

Company* (for corporate billing) / Name* (for individual billing + 21% VAT)

Address

City / Country*

Phone Number*

VAT Number for Company* (only for EU)

Post code*

Date

Payment method
- ○ Wire transfer
- ○ Credit card

Invoice billing information*
- ○ Corporate
- ○ Individual

Separate invoices required (for multiple registrations)
- ○ Yes
- ○ No

☐ By sending this form, I confirm that I have read and accepted the **Terms and Conditions**. To view the full Terms & Conditions and Privacy Policy terms, visit: https://etapapharma.com/docs/terms

To complete the registration process, fill out the form and send it to: accounting@etapaevents.com

Upon receiving the registration form, you will receive an invoice by email.

Sponsorship packages	Presentation ☐ €4,999	Silver ☐ €5,999	Gold ☐ €7,999	Platinum ☐ €11,499	Customize Your Package ☐ €xxx	Promo Materials Distribution ☐ €999
People attending	1	1	2	3	Exhibition wall on request, Coffee break, Lunch, Dinner, Cocktails, Lanyards, Workshop, Facility Tour …etc.	Distribution of your company's promotional materials to all conference attendees
Speaking slot	20 min		20 min	30 min		
Logo on the event website and brochure	◆	◆	◆	◆		
Discount on additional passes	10%	20%	30%	40%		
Promotional material distribution (provided by sponsor)	◆	◆	◆	◆		
Access to the delegate list	◆	◆	◆	◆		
Exhibition stands / roll-ups space		◆	◆	◆		
Ad placed in the final program			1/2 Page	Full page		
LCD Monitor for Video Presentations				◆		
Accommodation				◆		

**For more information on the packages and to discuss your sponsorships requirements, please contact: gabriela.vladimirova@vonlanthen-conferences.com / gabriela@etapahub.com*